On August 14, Oscar Health, Inc. rose 5.41% in regular trading, trading at $32.37/share, with turnover of $19.87 million. The stock continued its recent strong momentum following a blowout Q2 earnings report and a series of analyst upgrades.

Oscar Health posted Q2 EPS of $1.10, far exceeding the consensus estimate of $0.42-$0.49, representing a swing from a loss of $0.89 per share a year earlier. Revenue reached $4.88 billion, up from $2.86 billion year-over-year and beating the $4.73 billion estimate. Total effectuated membership surged 46% year-over-year to 2.963 million. The company reaffirmed full-year revenue guidance of $18.7-$19.0 billion, above the FactSet estimate of $18.55 billion.

On the institutional front, UBS raised its price target to $26 from $20 while maintaining a Neutral rating, and Barclays upgraded the stock to Overweight with a $35 target. Despite management warning that ACA membership churn may accelerate in the second half, the strong fundamental performance continues to attract capital inflows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)